EUVIMEDEUVIMED entdecken
Crossref

Renal recovery and clinical outcomes with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma with severe renal impairment

Yuichi Horigome, Hirotoshi Kamata, Koichi Ehata, Noriyuki Tadera, Kei Hayama, Takahiro Suzuki

International Journal of Hematology · 2026

DOI: 10.1007/s12185-026-04205-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, 2026. Verfasst von Yuichi Horigome und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan. horigome@med.kit…. Hauptthemen laut MEDLINE: Lenalidomide, Multiple Myeloma, Dexamethasone, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe renal impairment (RI) is a major contributor to early morbidity and mortality in transplant-ineligible newly diagnosed multiple myeloma (Ti-NDMM). Although daratumumab, lenalidomide, and dexamethasone (DRd) is an established frontline regimen, patients with creatinine clearance ≤ 30 mL/min were excluded from the MAIA trial, leaving evidence in this high-risk population limited. We retrospectively analyzed Ti-NDMM patients with severe RI, defined as estimated glomerular filtration rate (eGFR) ≤ 30 mL/min/1.73 m2, treated with frontline DRd between 2019 and 2024 at our institution. Ten patients met inclusion criteria, all classified as stage III according to the Second Revision of the International Staging System. The overall hematologic response rate was 80%, including very good partial response or better in 50%. Complete renal response occurred in 40% and was associated with deeper hematologic response and significantly prolonged progression-free survival and time to next treatment. Median eGFR improved from 21 to 50.5 mL/min/1.73 m2. These findings suggest that DRd is feasible and may provide clinically meaningful renal recovery and disease control in Ti-NDMM patients with severe RI, supporting its potential role as a frontline therapeutic option in this underrepresented population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LenalidomideMultiple MyelomaDexamethasoneAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsRenal InsufficiencyHumansMaleFemaleAgedTreatment OutcomeRetrospective StudiesGlomerular Filtration RateAged, 80 and overMiddle Aged

Stichwörter der Autor:innen

DaratumumabLenalidomideMultiple myelomaRenal responseSevere renal impairment

Substanzen

LenalidomideDexamethasonedaratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hematology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan. horigome@med.kitasato-u.ac.jp.
  • Department of Hematology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

Zitieren

APA

Horigome, Y., Kamata, H., Ehata, K., Tadera, N., Hayama, K., & Suzuki, T. (2026). Renal recovery and clinical outcomes with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma with severe renal impairment. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04205-2

Vancouver

Horigome Y, Kamata H, Ehata K, Tadera N, Hayama K, Suzuki T. Renal recovery and clinical outcomes with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma with severe renal impairment. International Journal of Hematology. 2026. doi:10.1007/s12185-026-04205-2

BibTeX
@article{Horigome2026,
  author = {Horigome, Yuichi and Kamata, Hirotoshi and Ehata, Koichi and Tadera, Noriyuki and Hayama, Kei and Suzuki, Takahiro},
  title = {Renal recovery and clinical outcomes with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma with severe renal impairment},
  journal = {International Journal of Hematology},
  year = {2026},
  doi = {10.1007/s12185-026-04205-2}
}
Kostenlos starten →